{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}],"title":"EF determined from cMRI at baseline and 3 months post-treatment."},{"measurements":[{"groupId":"OG000","value":"5"}],"title":"Delayed gadolinium enhancement from cMRI at baseline and 3 months post-treatment."}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"A reduction of 10% in left ventricular ejection fraction (LVEF) between the two cMRI studies was considered a subclinical functional event. New or progressive myocardial delayed enhancement within ≥1 segment was deemed as a subclinical structural event. Global left ventricle (LV) radial, circumferential, and longitudinal strain data for each patient were compared between cMRI-1 and cMRI-2.\n\nThe study had a fixed endpoint (3 months post-treatment)","groups":[{"description":"Doxorubicin hydrochloride: Standard therapy for patients undergoing chemotherapy for their non-Hogdkin's lymphoma and Hogdkin's lymphoma\n\nContrast-enhanced magnetic resonance imaging: Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake).","id":"OG000","title":"Contrast-enhanced Magnetic Resonance Imaging"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Ejection fraction (EF) and delayed gadolinium enhancement from cMRI at baseline and 3 months post-treatment will be determined and tested.","reportingStatus":"POSTED","timeFrame":"cMRI will be done prior to induction of doxorubicin based chemotherapy and at three months after completion of the doxorubicin based chemotherapy regimen.","title":"Left Ventricular Ejection Fraction (LVEF) and Global Strain Decrease After Doxorubicin Chemotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}